Patents by Inventor Jenna NGUYEN

Jenna NGUYEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NECTIN4 ANTIBODIES AND MULTI-SPECIFIC PROTEIN COMPLEXES COMPRISING SUCH
    Publication number: 20240368275
    Abstract: Antibodies that binds Nectin Cell Adhesion Molecule 4 (nectin-4) and multi-specific protein complexes comprising such anti-nectin4 antibodies, at least one additional antibody moiety binding to another target, and/or at least one cytokine moiety. Also provided herein are pharmaceutical compositions comprising such and uses thereof.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 7, 2024
    Applicant: Elpis Biopharmaceuticals
    Inventors: Kehao Zhao, Yan Chen, Jenna Nguyen, Suga Subramaniam, Ning Jiang
  • ANTIBODIES SPECIFIC TO SIALIC ACID-BINDING IG-LIKE LECTIN 15 AND USES THEREOF
    Publication number: 20240336683
    Abstract: Disclosed herein are high affinity anti-Siglec 15 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-Siglec 15 antibodies.
    Type: Application
    Filed: March 18, 2022
    Publication date: October 10, 2024
    Applicant: Elpis Biopharmaceuticals
    Inventors: Kehao ZHAO, Yan CHEN, Samuel Clement HASSAN, Jenna NGUYEN, Ning JIANG
  • BISPECIFIC CHIMERIC ANTIGEN RECEPTORS BINDING TO CD19 AND CD22
    Publication number: 20240082402
    Abstract: Bi-specific chimeric antigen receptors (CARs) capable of binding to both CD19 and CD22 and immune cells expressing such. Also provided herein are therapeutic uses of such immune cells (e.g., CAR-T cells) for eliminating disease cells such as cancer cells.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 14, 2024
    Applicant: Elpis Biopharmaceuticals
    Inventors: Yan CHEN, Jenna NGUYEN, Kehao ZHAO, Keming ZHANG
  • ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
    Publication number: 20230220053
    Abstract: Disclosed herein are anti-SARS-CoV-2 spike protein antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such antibodies.
    Type: Application
    Filed: May 17, 2021
    Publication date: July 13, 2023
    Applicant: Elpis Biopharmaceuticals
    Inventors: Yan CHEN, Kehao ZHAO, Jenna NGUYEN, Ning JIANG
  • ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS
    Publication number: 20230002466
    Abstract: Provided herein are engineered IL2 polypeptides and fusion proteins thereof. Also provided are methods of modulating an immune response by administering an engineered IL2 polypeptide or a fusion protein thereof. The engineered IL2 polypeptides and fusion proteins thereof demonstrate increased binding to IL2R?, decreased binding to IL2R?, or both.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 5, 2023
    Inventors: Yan CHEN, Kehao ZHAO, Christina SWANSON, Jenna NGUYEN, Nathan KALLEN, Samuel Clement HASSAN, Ning JIANG
  • ANTI-CD22 ANTIBODIES AND USES THEREOF
    Publication number: 20220298257
    Abstract: Disclosed herein are high affinity anti-CD22 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-CD22 antibodies.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 22, 2022
    Inventors: Yan CHEN, Jenna NGUYEN, Kehao ZHAO
  • ANTI-CD19 ANTIBODIES AND USES THEREOF
    Publication number: 20220289843
    Abstract: Disclosed herein are high affinity anti-CD19 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-CD19 antibodies. The anti-CD19 antibodies disclosed herein showed high stability as determined by thermal shift assays and bind different CD19 epitopes as FMC63. The anti-CD19 antibody clone used for developing immunotherapeutic agents such as tisagenlecleucel.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Inventors: Yan CHEN, Jenna NGUYEN, Kehao ZHAO